Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.

@article{Lassen1998EfficacyAS,
  title={Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.},
  author={Michael Rud Lassen and Lars Carl Borris and Bradley S Anderson and Hans Peter Jensen and H P Skej\o Bro and Grethe Andersen and Andreas Overbeck Petersen and P Siem and Erik H\orlyck and Benny Vittrup Jensen and Per B Thomsen and Birgitte R\onde Hansen and J Erin-Madsen and Jens Chr. M\oller and L B Rotwitt and Frances Christensen and John Bugge Nielsen and Per Seest J\orgensen and B P Paaske and Carsten T\orholm and P Hvidt and Noelle K Jensen and Allan Bybeck Nielsen and E Appelquist and E Tjalve},
  journal={Thrombosis research},
  year={1998},
  volume={89 6},
  pages={281-7}
}
The aim of this study was to compare the efficacy and safety of prolonged (35 days) thromboprophylaxis with a standard length (7 days) regimen of a low molecular weight heparin in patients undergoing total hip arthroplasty. The study was multicentre, randomised, double-blind, and prospective with two groups. Following seven days on a standard length regimen… CONTINUE READING